Categories: News

Seacoast Capital Exits Non-Control Growth Capital Investment in Walden Behavioral Care

BOSTON, Oct. 27, 2021 /PRNewswire/ — Seacoast Capital (“Seacoast”), a lower middle market non-control growth capital investor, announced today its exit from its investment in Walden Behavioral Care (“Walden” or “the Company”). Over the term of Seacoast’s investment, the Company nearly doubled revenue, EBITDA, and its daily patients served. Seacoast exited its investment in Walden in a sale to Monte Nido & Affiliates, one of the country’s leading eating disorder treatment providers.

Seacoast helped us navigate growth opportunities, stayed through strategy changes and made additional capital available.

Founded in 2003 by Stuart Koman, Ph.D., and headquartered in Waltham, Massachusetts, Walden is one of the premier providers of behavioral health services for individuals with eating and mood disorders. The Company was one of the first healthcare providers in the country to offer a full continuum of medical, behavioral, and nutritional care services for the treatment of eating disorders across inpatient, residential, partial hospitalization, and intensive outpatient care settings. 

In June 2014, Seacoast initially invested in Walden to assist with the organic growth of the business. Seacoast then made two follow-on investments in the Company in 2017 and 2019 to further expand Walden’s geographic footprint into the Atlanta market and to build a new hospital in Dedham, Massachusetts. In total, Seacoast invested $11.25 million in subordinated debt and preferred stock in Walden over its 7-year hold period.

“Seacoast Capital has been a great partner for us,” said Dr. Koman. “They’ve helped us navigate our many expansion opportunities, stayed with us through strategy changes due to the pandemic, and made additional capital available as we continued to scale. We’ve appreciated having Seacoast on our Board.”

Stu Koman and his team have always been committed first to their patients. The work they do in helping people of all ages with eating and mood disorders has been remarkable—they save lives every day,” said Tom Gorman, a Partner at Seacoast Capital. “In addition, the Walden team’s ability to make keen business decisions and expand during the pandemic is testament to their abilities. We will miss being a part of the Walden team.”

In addition, Alan Rich, a Vice President at Seacoast Capital, said, “Walden’s ability to leverage their multi-channel delivery model showed the agility of the team across every care setting. We wish Walden well as they commence their next chapter with Monte Nido.”

About Seacoast Capital
Founded in 1994, with offices in Boston, MA and San Francisco, CA, Seacoast Capital invests non-control growth capital in partnership with management in lower middle market companies. Seacoast is industry agnostic and typically invests $5 million to $25 million of capital in companies with $10 million or more in revenue and $2 million or more of EBITDA. Capital is used to support growth, refinancings, acquisitions, family wealth and ownership transfers, shareholder liquidity events, and partnership or management buyouts. Geographically, Seacoast invests anywhere in the United States. Since its inception, Seacoast has managed over $600 million of capital, which the firm has invested in 82 non-controlling transactions. Now managing its fourth fund, Seacoast Capital Partners IV, L.P., the firm continues to actively seek new investment opportunities. Learn more by visiting www.seacoastcapital.com.

Submit inquiries to:
Phil Curatilo, Principal & CMO
Seacoast Capital
(978) 750-1319
pcuratilo@seacoastcapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seacoast-capital-exits-non-control-growth-capital-investment-in-walden-behavioral-care-301409263.html

SOURCE Seacoast Capital Managers LLC

Staff

Recent Posts

ZetrOZ System’s sam(R) Ultrasound Treatment Helps Top Triathlete Return to the Boston Marathon

Former triathlon champ Claudia McCoy used the breakthrough wearable ultrasound unit to boost her recovery…

48 minutes ago

Coro Medical Prepares to Roll Out Project AED365 Nationwide Donation Initiative

Project AED365 Aims to Empower Communities, Youth Organizations, First Responders, and more by Providing Lifesaving Automated…

4 hours ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages…

4 hours ago

Blazesoft Spreads Holiday Cheer with $250,000 Donation to Mackenzie Health Foundation

This heartfelt donation demonstrates Blazesoft's commitment to corporate social responsibility with a generous gift to…

4 hours ago

Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

GOLETA, Calif.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products…

7 hours ago

Bemax Inc. Announces Second Quarter Financial Results

- Revenue grew to $1,078,090, an increase of over $1million year-over-yearDallas, Georgia--(Newsfile Corp. - December…

7 hours ago